PYC Therapeutics
Nedlands · Founded 2005
About PYC Therapeutics
PYC Therapeutics is a clinical-stage biotechnology company specializing in RNA-based therapies targeting genetic diseases. It leverages a proprietary delivery system using cell-penetrating peptides (CPPs) conjugated to phosphorodiamidate morpholino oligomers (PMOs) to enhance cellular uptake. The company’s pipeline focuses on inherited conditions affecting the eye, central nervous system, and kidney, including ongoing Phase 1 and natural history studies.
Company Facts
- Founded: 2005
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $26.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2024)
- Ticker: asx:PYC
- Website: http://www.pyctx.com/
- Phone: +61 8 6151 0992
Industries & Categories
Biopharma, Biotechnology, Clinical Trials
Social Profiles
Canonical: https://fsome.com/organization/pyc-therapeutics-165873 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.